FOXO4-DRI — senolytic peptide, is anyone trialing?
23 posts
FOXO4-DRI is the senolytic peptide that got attention after the 2017 Baar et al paper. Disrupts the FOXO4-p53 interaction, allegedly inducing apoptosis preferentially in senescent cells. Is anyone actually running this outside rodents?
6 Replies
117 posts
The Baar paper was interesting in mice. Human trials are basically zero. Running FOXO4-DRI as an individual is way outside the evidence base. This is the class of peptide where 'nobody has done it' is a feature, not a bug.
34 posts
Inducing apoptosis in senescent cells is a nice idea. Inducing apoptosis off-target is a much worse idea. Without human PK/safety data I wouldn't touch this.
212 posts
Agreed. Senolytics are a real frontier. FOXO4-DRI specifically is not ready for human self-experimentation IMO. Dasatinib + quercetin has more human exposure if you're determined to do something in this space.
- CJC-1295 no DAC · 100 mcg · pre-bed · sub-Q
- Ipamorelin · 200 mcg · pre-bed · sub-Q
- BPC-157 · 500 mcg · 2x/day · sub-Q
50 posts
Yeah the risk/reward just doesn't make sense here. You're basically a test subject for off-target apoptosis with zero human dosing data. Dasatinib + quercetin at least has some real world experience behind it.
- Tirzepatide · 5 mg · weekly · sub-Q
20 posts
Yeah hard pass. The gap between "works in mice" and "safe in humans" is basically a canyon with this one. Dasatinib + quercetin is the move if you want to actually do something.